Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1537 • ACR Convergence 2025
Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Melanie Hagen¹, Fabian Müller², Andreas Wirsching¹, Soraya Kharboutli³, Silvia Spoerl³, Christina Duesing⁴, Tobias Krickau⁵, Markus Metzler⁵, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Ingrid Vasova³, Marc Saake⁵, Stefan Schliep⁵, Torsten Kubacki⁶, Nicolas Hunzelmann⁶, Laura Bucci¹, Jule Taubmann⁷, Christina Bergmann¹, Andrea-Hermina Györfi⁸, Sascha Dietrich⁹, Jörg Distler¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Klinik für Rheumatologie, Düsseldorf, Germany, ⁵Friedrich-Alexander-Universität Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁶University and University Hospital Cologne, Cologne, Germany, Cologne, Germany, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁹Heinrich Heine University Duesseldorf, University Hospital Duesseldorf, Duesseldorf, Germany, ¹⁰University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment strategies for severe B-cell driven autoimmune diseases (AID) like Systemic Lupus erythematosus (SLE), Systemic…
Abstract Number: 1519 • ACR Convergence 2025
Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study
Anca Askanase¹, Bruno Flamion², Ouali Berkani² and Cecile Dubois², ¹Columbia University Medical Center, New York, NY, ²Viatris Innovation, Allschwil, Switzerland
Background/Purpose: Cenerimod is a highly selective S1P1 receptor modulator which is undergoing trials for potential therapeutic benefits in autoimmune disease, including Systemic Lupus Erythematous (SLE).…
Abstract Number: 1495 • ACR Convergence 2025
Comparing the 0-10 Physician Global Assessment Scale to Categorical Disease Activity States among Pediatric Patients with SLE
Livie Timmerman¹, Melissa Mannion² and Emily Smitherman², ¹University of Alabama at Birmingham, Gardendale, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Physician Global Assessment (PGA) is used to measure disease activity on a 0–10 scale for many pediatric rheumatic conditions. However, the thresholds at…
Abstract Number: 1478 • ACR Convergence 2025
Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
Bin Zhou¹, QIn Huang², Pan Wang³ and Qiguo Cui⁴, ¹Nanfang Hospital, Guangzhou, Guangdong, China (People's Republic), ²Nanfang Hospital, Guangzhou, China (People's Republic), ³southern medical university Nanfang Hospital, Guangzhou, China (People's Republic), ⁴Southern Medical Univercity Nanfang Hospital, guang zhou, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs. Cognitive dysfunction (CD) is a common but often underestimated complication in…
Abstract Number: 1295 • ACR Convergence 2025
Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America
Martha Rodriguez¹, Ekemini Ogbu², Ashley Danguecan³, Marietta De Guzman⁴, Alexandra Theisen⁵, Lawrence Ng⁶, Andrea Knight³ and Ryann Kammeyer⁷, ¹Riley Hospital For Children at Indiana University, Indianapolis, IN, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Hospital for Sick Children, Toronto, ON, Canada, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Arkansas, Little Rock, AR, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷University of Colorado, Denver, CO
Background/Purpose: Neuropsychiatric involvement in Systemic Lupus Erythematosus (NPSLE) is a major cause of morbidity and mortality, particularly among children who are still developing neurologically. Despite…
Abstract Number: 1235 • ACR Convergence 2025
Demystifying Pain in patients with Lupus: How much is it Lupus and How much is it Other Stuff?
Meenakshi Jolly, Rush University, Chicago
Background/Purpose: Pain in patients with Systemic Lupus Erythematosus (SLE) is not well understood. There is role of active disease in pain (e.g. arthritis, serositis) also…
Abstract Number: 1050 • ACR Convergence 2025
Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care
Isabella Hartel¹, Jay Patel¹, David Gazeley², Drake Johnson¹, Justin Levinson¹, Carmen Campbell¹, Britney Youngchild³, Shelby Gomez³, Amannda Weber⁴, Jessica Michaud⁵, Laura Dickmann⁶, Sancia Ferguson⁷, Betty Chewning⁸, Christie Bartels⁹ and Shivani Garg¹⁰, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Wisconsin, School of Pharmacy, Madison, WI, ⁴University of Wisconsin (UW), UW Health, Madison, WI, ⁵Medical College of Wisconsin, Milwaukee, Madison, WI, ⁶Medical College of Wisconsin, Milwaukee, Milwaukee, ⁷University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, ⁸University of Wisconsin, School of Pharmacy, Madison, ⁹University of Wisconsin School of Medicine and Public Health, Madison, WI, ¹⁰University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is a key therapy for lupus (or SLE). Yet, challenged to weigh benefits vs. harms, ~80% of patients self-discontinue HCQ. Shared decision-making…
Abstract Number: 0938 • ACR Convergence 2025
Short Term Antibiotic Treatment Improves the Neurobehavioral Phenotype of MRL/lpr Mice
Melodie Zaknoun¹, Doaa Tehawey¹, Baruh Polis¹ and Chaim Putterman², ¹Azrieli Faculty of Medicine, Safed, Israel, ²Albert Einstein College of Medicine, Safed, Israel
Background/Purpose: Neuropsychiatric lupus (NPSLE) is a common and prognostically significant manifestation of SLE, affecting 20-40% of lupus patients. The ACR identified 19 clinical syndromes associated…
Abstract Number: 0670 • ACR Convergence 2025
Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extra-renal Systemic Lupus Erythematosus – A Systematic Review & Meta-analysis
Zahraa Qamhieh¹, Dalia Sriwi¹, Callie Saric², Tripti Singh³, Christie Bartels⁴ and Shivani Garg⁵, ¹University of Wisconsin, Madison, Department of Medicine, Madison, WI, ²University of Wisconsin, Madison, School of Medicine and Public Health, Madison, WI, ³University of Wisconsin, Madison, Department of Nephrology, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Clinical response to Mycophenolic acid (MPA) is highly heterogeneous; thus, therapeutic drug monitoring (TDM) of MPA could help improve treatment efficacy. Our objective in…
Abstract Number: 0646 • ACR Convergence 2025
A-319, a CD3×CD19 T Cell Engager, for the Treatment of Refractory Systemic Lupus Erythematosus: Preliminary Evidence of Autoimmune Reset
Chunli Mei¹, Xin Guan¹, Rong Du¹, Bin Wu², You Song¹, Xiaoqi Chen³, Mengjiao Li¹, Xiaojing Liu¹, Xi Cheng¹, Weiwei Wang¹, Cheng Wang¹, Huiling Mei¹, Xiaoru Duan¹, Lijuan Jiang¹, Wenlin Qiu¹, Likai Yu¹, Yuhong Liu¹, Di Wu¹, Guiqi Quan¹, Blal Chakhabi¹, Xing Zhao⁴, Xuanfan Zhong⁴, Shengjie Xue⁴, Wuzhong Shen⁴, Ying Tan⁴, Guojian Yu⁴, Guiyun Tu⁴, Hanyang Chen⁴, Amy Sun⁴, Jing Liang⁴, Sharon Song⁴, Jason Xu⁴, Xiaoqiang Yan⁴, Anbing Huang¹ and Qiubai Li⁵, ¹Union Hospital,Tongji Medical College, Huazhong University of Science and Technology, WUHAN, China (People's Republic), ²First People’s Hospital of Jingzhou, Jingzhou, China (People's Republic), ³Zhongnan Hospital, Wuhan University, Wuhan, China (People's Republic), ⁴ITabMed Co., Ltd., Shanghai, China (People's Republic), ⁵Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic)

Background/Purpose: Immune reset of autoimmune disease has been proposed to be a potential benefit of T cell engagers (TCEs) and CD19 CAR T therapy. A-319,…
Abstract Number: 0624 • ACR Convergence 2025
Polygenic risk of lupus is differentially associated with individual EHR-derived classification criteria
Noah Forrest¹, Sachleen Tuteja², Jennifer Pacheco³, Vesna Mitrovic³, Rosalind Ramsey-Goldman¹, Theresa Walunas³ and Matthew Dapas¹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Evanston, ³Northwestern University Feinberg School of Medicine, Chicago
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by diverse clinical presentation, posing significant challenges in diagnosis and management. Reflecting this clinical…
Abstract Number: 0608 • ACR Convergence 2025
Strong Correlation Between SLEDAI and SLE-DAS in the Spanish Population: Assessment of Discordant Patients
Elena Heras Recuero¹, Antia Garcia Fernandez², Cristina Gomez-Moreno³, Ivan Ferraz Amaro⁴, Javier Llorca⁵ and Miguel A. González-Gay⁶, ¹Hospital Fundacion Jimenez Dias, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ³Fundacion Jiménez Díaz School of Nursing, Madrid, Autonomous University Madrid, Madrid, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, ⁶Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
Background/Purpose: Assessing disease activity in systemic lupus erythematosus (SLE) is essential for effective treatment. SLEDAI-2K uses dichotomous items, while SLE-DAS incorporates both dichotomous and continuous…
Abstract Number: 0885 • ACR Convergence 2025
MAIT cell-mediated immune modulation in lupus: antigen-driven expansion as a protective strategy
Grace Crossland¹, lennard Ostendorf², Vianey Chavez¹, Lindsay Mendyka¹, Deepak Rao³ and Sladjana Skopelja-Gardner¹, ¹Dartmouth College, Lebanon, NH, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of death for young women, and over 75% of SLE patients experience skin manifestations – cutaneous…
Abstract Number: 0791 • ACR Convergence 2025
Disagreements in Disease Activity Measures in an Evaluation of SLE Outcome Measures in Telemedicine
Leila Khalili¹, Cynthia Aranow², Mimi Kim³, Diane Kamen⁴, Cristina Arriens⁵, Alberto Nordmann-Gomes⁶, Maya Souvignier⁶, Wei Tang⁷, Stephen Suh⁸, Maria Dall'Era⁹, Meghan mackay¹⁰ and Anca Askanase¹, ¹Columbia University Medical Center, New York, NY, ²Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Medical University of South Carolina, Johns Island, SC, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Columbia University Irving Medical Center, New York, NY, ⁷Westchester Medical Center, Valhalla, NY, ⁸Columbia University Irving Medical Center, New York City, NY, ⁹Division of Rheumatology, University of California, San Francisco, CA, ¹⁰Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: We previously described the top-line results of our study and the high correlations between virtual SLE disease activity measures (DAM) and those obtained during…
Abstract Number: 0196 • ACR Convergence 2025
Increasing Timely Rheumatology Evaluation for High Risk Lupus Patients
Steven Taylor¹ and Elena Weinstein², ¹University of Colorado, Denver, CO, ²University of Colorado, Englewood, CO
Background/Purpose: The rheumatology workforce shortage presents many challenges to the delivery of rheumatology care. Improving timely access to rheumatology for patients with life or organ…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].